HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aripiprazole is effective for treatment of delayed sleep phase syndrome.

Abstract
Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.
AuthorsManabu Takaki, Hiroshi Ujike
JournalClinical neuropharmacology (Clin Neuropharmacol) 2014 Jul-Aug Vol. 37 Issue 4 Pg. 123-4 ISSN: 1537-162X [Electronic] United States
PMID24992089 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antipsychotic Agents
  • Piperazines
  • Quinolones
  • Aripiprazole
Topics
  • Adult
  • Antipsychotic Agents (therapeutic use)
  • Aripiprazole
  • Female
  • Humans
  • Piperazines (therapeutic use)
  • Quinolones (therapeutic use)
  • Sleep Disorders, Circadian Rhythm (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: